COMMUNIQUÉS West-GlobeNewswire
-
Applied Biologics Announces Completion of Translational Research Supporting the Biologic Performance of XWRAP®
24/06/2026 -
SoldierStrong Donates Real® i-Series System to VA Boston Healthcare System to Advance Veteran Wellness and Mental Health Care
24/06/2026 -
Rendever Brings Social Prescribing to Senior Living with CommunityOS
24/06/2026 -
Noom Launches Free Version of Its Powerful GLP-1 Companion — Empowering Providers with a Research-Backed Tool to Support Weight Loss That Lasts
24/06/2026 -
Labviva Launches “The Agentic Crew”: A Purpose-Built AI Architecture to Transform Procurement in Regulated Industries
24/06/2026 -
Caregivers in Crisis: New Survey from Aeroflow Urology Reveals 77% of Caregivers are Drowning in Costs as Out-of-Pocket Expenses Reach a Breaking Point
24/06/2026 -
Femasys Regains Compliance with Nasdaq Listing Requirements
24/06/2026 -
Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts
24/06/2026 -
Bionano Announces Hiring of Chief Scientific Officer
24/06/2026 -
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
24/06/2026 -
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume
24/06/2026 -
Onconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District
24/06/2026 -
Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases
24/06/2026 -
Picard Medical Announces Leadership Transition
24/06/2026 -
Noom Members Regained 3x Less Weight After Stopping GLP-1s vs Standard-of-Care, New Analyses Show
24/06/2026 -
BrewDog and Tilray Beer Are Ready to Pour the World’s Biggest Bar Tab — £1 Million of Free Pints
24/06/2026 -
Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit
24/06/2026 -
The Quest to Repair What Multiple Sclerosis Takes Away
24/06/2026 -
AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones
24/06/2026
Pages